Oligometastatic Prostate Cancer Ompc clinical trials

Explore recruiting oligometastatic prostate cancer ompc clinical trials.

Recruiting oligometastatic prostate cancer ompc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Oligometastatic Prostate Cancer Ompc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)

France, Czechia, Spain, Belgium, Italy, Slovakia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Oligometastatic Prostate Cancer Ompc trials by city

Oligometastatic Prostate Cancer Ompc in Toronto Oligometastatic Prostate Cancer Ompc in Vancouver Oligometastatic Prostate Cancer Ompc in Montreal Oligometastatic Prostate Cancer Ompc in Calgary Oligometastatic Prostate Cancer Ompc in Edmonton Oligometastatic Prostate Cancer Ompc in Ottawa Oligometastatic Prostate Cancer Ompc in Winnipeg Oligometastatic Prostate Cancer Ompc in Quebec City Oligometastatic Prostate Cancer Ompc in Hamilton Oligometastatic Prostate Cancer Ompc in Kitchener Oligometastatic Prostate Cancer Ompc in London Oligometastatic Prostate Cancer Ompc in Halifax Oligometastatic Prostate Cancer Ompc in New York Oligometastatic Prostate Cancer Ompc in Los Angeles Oligometastatic Prostate Cancer Ompc in Chicago Oligometastatic Prostate Cancer Ompc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease